Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

被引：0
|
作者：
Huihui Li
Fengli Hu
Yanli Zhang
Kai Li
机构：
[1] Heze Municipal Hospital,Department of Neurology
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Disease-modifying therapy; Relapsing–remitting multiple sclerosis; Systematic review; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3489 / 3498
页数：9
相关论文
共 50 条
  • [41] Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis
    Giannopapas, Vasileios
    Smyrni, Vassiliki
    Kitsos, Dimitrios K.
    Stefanou, Maria Ioanna
    Theodorou, Aikaterini
    Tzartos, John S.
    Tsivgoulis, Georgios
    Giannopoulos, Sotirios
    JOURNAL OF NEUROLOGY, 2025, 272 (02)
  • [42] Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis
    Dang, Yew Li
    Yong, Vivien T. Y.
    Sharmin, Sifat
    Perucca, Piero
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 657 - 667
  • [43] Discontinuation of disease-modifying therapies in relapsing remitting multiple sclerosis - outcome and prognostic factors
    Bsteh, G.
    Feige, J.
    Ehling, R.
    Hegen, H.
    Auer, M.
    Di Pauli, F.
    Deisenhammer, F.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 644 - 644
  • [44] Safety of disease modifying drugs in pregnant women with relapsing-remitting multiple sclerosis: Systematic review and meta-analysis
    Sarmento, Tulio Tadeu R.
    Zuppo, Isabella F.
    Azevedo, Pamela S.
    Ribeiro, Nelio G.
    Brandao, Natalia D.
    Nader, Carolina M. F. F.
    Gargano, Ludmila P.
    Acurcio, Francisco A.
    Alvares-Teodoro, Juliana
    Guerra, Augusto A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 548 - 549
  • [45] Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Lucchetta, Rosa C.
    Leonart, Leticia P.
    Goncalves, Marcus V. M.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    PLOS ONE, 2020, 15 (06):
  • [46] Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Marita Zimmermann
    Elizabeth Brouwer
    Jeffrey A. Tice
    Matt Seidner
    Anne M. Loos
    Shanshan Liu
    Richard H. Chapman
    Varun Kumar
    Josh J. Carlson
    CNS Drugs, 2018, 32 : 1145 - 1157
  • [47] Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 34 - 35
  • [48] Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Martinez-Lopez, Iciar
    Maurino, Jorge
    Sanmartin-Fenollera, Patricia
    Ontanon-Nasarre, Ana
    Santiago-Perez, Alejandro
    Moya-Carmona, Isabel
    Gustavo Garcia-Collado, Carlos
    Fernandez-Del Olmo, Raquel
    Garcia-Arcelay, Elena
    Sarmiento, Monica
    Carreno, Agata
    Perez-Encinas, Montserrat
    PHARMACY, 2020, 8 (02)
  • [49] Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
    Tian, Xin
    Chen, Chaoyang
    Ma, Lingyun
    Wei, Ran
    Li, Min
    Wang, Xiaoqing
    Wu, Ye
    Zhou, Ying
    Cui, Yimin
    JOURNAL OF NEUROIMMUNOLOGY, 2020, 347
  • [50] Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
    Hu, Yang
    Nie, Hao
    Yu, Hai-Han
    Qin, Chuan
    Wu, Long-Jun
    Tang, Zhou-Ping
    Tian, Dai-Shi
    AUTOIMMUNITY REVIEWS, 2019, 18 (05) : 542 - 548
12345